Physician profile
Rishin C Patel
NPI 1730434291
$659.81
in general payments reported to CMS, 2019-2025
14 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.28 · 2020: $23.24 · 2023: $221 · 2024: $123 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.67 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $155.27 | 2023-2025 | Nucala, Arexvy |
| Abbvie INC. | $105.65 | 2023-2024 | |
| Dexcom, INC. | $80.12 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $73.66 | 2023-2024 | Mounjaro, Jardiance |
| Abbott Laboratories | $46.10 | 2024-2025 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $44.52 | 2023 | |
| Seqirus USA INC | $33.88 | 2024 | Fluad, Flucelvax |
| E.R. Squibb & Sons, L.L.C. | $23.24 | 2020 | |
| Pfizer INC. | $22.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.63 | 2023 | Spravato |
| Merck Sharp & Dohme LLC | $16.39 | 2025 | Vaxelis, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $15.04 | 2023 | Breztri |
| Amgen INC. | $15.03 | 2025 | Otezla, Repatha |
| Novo Nordisk INC | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.